P. A-M

Ronin Haematologist

[Genetic Engineering & Biotechnology News @GENbio]

Large Bioprinted Tissues Get a Precision Boost

Researchers develop a perfusion platform improving control, monitoring, and scalability of large bioprinted tissue cultures
@UnivLyon1
#NextGEN #bioprinting #bioreactor
https://t.co/mIl12l8Ibw

[Stem Cell Podcast @stemcellpodcast]

🚨 Something big is coming!

20 years after the discovery of #iPSCs, we're sitting down with the scientist behind it all.

Dr. Shinya Yamanaka, @NobelPrize Laureate, joins us to discuss the discovery that changed regenerative medicine and where we're headed next.

📃 https://t.co/yk4ImOk4SL

[Diario Médico @diariomedico]

🧬#DíaMundialDelARN | La molécula que pasó de estar a la sombra del ADN a liderar la revolución biomédica.

💉Vacunas, edición genética, cáncer y mucho más. 🚀

#ARN #InvestigaciónCientífica https://t.co/GRFTtDGd6i

[Genetic Engineering & Biotechnology News @GENbio]

Capsid Experts Hope to Slash the Cost of Gene Therapies

Capsid experts at #AffiniaTherapeutics hope to cut adeno-associated virus therapy manufacturing costs with plasmid engineering

#NextGEN #genetherapy #biomanufacturing #AAV
https://t.co/YftE7j9SIi

[BioSpace @biospace]

The FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo.

https://t.co/fxDYLnmnqS

[Alliance for Regenerative Medicine (ARM) @alliancerm]

Announcing the release of ARM's Q2 2026 Cell & Gene Therapy Sector Snapshot and H1 2026 CGT Sector Data! 🧬 📊

Dive into the full publication below.
➡️ https://t.co/7UPe0JlO2b

[Genetic Engineering & Biotechnology News @GENbio]

Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD

A Phase III trial found the donor-derived cell therapy deramiocel slowed arm muscle decline in boys and young men with advanced DMD
@US_FDA
#clinicaltrial #celltherapy #DMD
https://t.co/3PbXffMlht

[Pluchino lab - Regenerative Neuroimmunology @Pluchinolab]

Programmable delivery of mitochondria to specific cell types | Nature Reviews Molecular Cell Biology https://t.co/nCSCO7axQX

[Muscle Cell News @musclecellnews]

New from @UCSanDiego! 📣

Researchers constructed a multimodal cell atlas of 36 human hearts spanning atrial and ventricular chambers, cataloging major #cardiac cell types and their associated disease states. ❤️ https://t.co/0xlhjVbay5

They demonstrate that heart failure pathogenesis involves the coordinated disruption of cell type–specific gene-regulatory networks.

Read the article in @Science. 📖

[Medscape @Medscape]

Generic injectable semaglutide could cost as little as $28 per person-year after the initial patent expired in April 2026 — a fraction of current branded prices — and be available in about 162 countries by the end of 2026, covering roughly 69% of the global type 2 diabetes (T2D) burden and 84% of the clinical obesity burden.

“Lower prices through generic access could enable earlier intervention for obesity, integration into primary care, and a shift from treating advanced metabolic complications toward preventing long-term morbidity,” the authors of the study wrote. https://t.co/2cQdBI9sMf

[Diario M��dico @diariomedico]

🔬 El cribado de #CáncerDePulmón empieza a dar resultados: 30 casos detectados en 6 meses con CASSANDRA. La detección precoz puede cambiarlo todo. https://t.co/nkxgc7znbk

[Diario Médico @diariomedico]

🧬@EliLillyandCo quiere revolucionar la industria farmacéutica con #IA: de 2.000 moléculas al año a analizarlas en horas gracias a LillyPod, su supercomputador con Nvidia.

🗣️ Lo cuenta Teresa Millán, directora de Asuntos Corporativos.

✍@cgr1511 https://t.co/Z2nX5csaWs

[Nature Medicine @NatureMedicine]

A first-in-human phase 1 study of an allogeneic, clinical-grade #iPSC-derived neural stem/progenitor cell product in patients with subacute complete #SpinalCordInjury demonstrates clinical #feasibility and long-term #safety. #SCI #StemCellTherapy #RegenerativeMedicine

https://t.co/wWU3CU7lBz

[BioSpace @biospace]

Facing pressure around the world to withdraw the rare kidney disease drug Tavneos, Amgen has launched a robust defense with real-world evidence to support the product’s benefit-risk profile.

https://t.co/Wb7LYxqfYg

[nature @Nature]

A tailored treatment has reduced seizures and improved developmental skills in two boys with debilitating neurological disorders

https://t.co/5OGw8L9b44

[Genetic Engineering & Biotechnology News @GENbio]

Autism-Like Traits in Mice Improved After Single Rapamycin Dose

Study findings point to possible autism therapeutic approaches that target the underlying pathways rather than only symptoms
@UCLAHealth
#autismspectrumdisorder #inflammation #mice
https://t.co/K4b5Xsnz7D

[nature @Nature]

Nature research paper: Tertiary lymphoid structures harbour stem-like tumour-specific T cells

https://t.co/z0jTImqKMM

[Diario Médico @diariomedico]

🤖La #IA ya transforma los #EnsayosClínicos: agiliza el reclutamiento, mejora la trazabilidad y refuerza la seguridad del paciente.

💬"Digitalizar estos procesos ya no es una opción, sino una necesidad", destaca Lucía Llanos. https://t.co/bpPUNMjcyX

[BioSpace @biospace]

With weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Earlier data from TRIUMPH-1 showed weight loss reaching a record-breaking 28.3%.

https://t.co/5FhOaMYbyc

[Nature Biotechnology @NatureBiotech]

Biotech is back. But continued investor caution, the rise of China and fast-moving AI are changing the sector’s contours https://t.co/NyxguQ8qL5
[🔓read free with login]